ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2542

La Positive, Ro60 Negative Subset of Primary Sjögren’s Syndrome Is a Reality

Debashish Danda1, Dat Truong2, Marshall Shaw3, Celia Quang3, Kristi A. Koelsch4, Biji T. Kurien5, Harini Bagavant2, Umesh Deshmukh2 and R. Hal Scofield6, 1Clincial Immunology and Rheumatology, Christian Medical College, Vellore, India, Vellore, India, 2Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Okalahoma City, OK, 5U.S. Department of Veterans Affairs Medical Center, Oklahoma City, OK, 6US Department of Veterans Affairs Medical Center, Oklahoma City, OK

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Sjogren's syndrome and autoantibodies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Sjogren's Syndrome: Clinical Science

Session Type: Abstract Submissions (ACR)

Background/Purpose

Twenty-nine sera from 348 primary Sjögren’s syndrome patients were identified as anti-Ro60 (anti-SSA) negative and anti-La (anti-SSB) positive by immunodiffusion, line immunoassays and multiplex bead assays. We hypothesize that a significant portion of these are falsely negative for anti-Ro60.  

Methods

Twenty-nine sera from primary Sjögren’s syndrome patients, fulfilling four AECG criteria, were tested for the presence of antibodies directed against La and Ro60 autoantigen. Anti-La was detected on bovine La treated with or without DNAase and RNAase (to check for false positivity, since anti-La can bind DNA and RNA). Anti-Ro60 antibodies in the sera were detected using HEp-2000 substrate (in which cells are transfected with human Ro60) and HEp-2 substrate. Anti-Ro60 and Ro-52  were also tested by in vitrotranscription/translation/immunoprecipitation assay.  

Results

Out of the 29 sera, 25 were unequivocally negative on HEp-2000 (1:40 dilution). Four samples were clearly found to be Ro60 positive with a speckled pattern and three of the four continued to be positive up to 1:320 dilution, as against only two positive samples on HEp-2 at 1:40 dilution. This finding suggests false negativity for Ro60 exists in a small fraction (14 percent) of primary Sjogren’s syndrome patients. However, all the samples were negative for Ro60 and Ro52 by in vitrotranscription/translation/immunoprecipitation assay. 

Conclusion

Contrary to our hypothesis, we found only a small fraction of Ro negative, La positive sera to show positive HEp-2000 pattern. This suggests that a subset of primary Sjogren’s syndrome is probably a true entity with Ro60 negativity and La positivity. The clinical significance of the subset will be revealed during the follow up of our patients.


Disclosure:

D. Danda,
None;

D. Truong,
None;

M. Shaw,
None;

C. Quang,
None;

K. A. Koelsch,
None;

B. T. Kurien,
None;

H. Bagavant,
None;

U. Deshmukh,
None;

R. H. Scofield,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/la-positive-ro60-negative-subset-of-primary-sjogrens-syndrome-is-a-reality/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology